All Company Profiles

Deck Bio

April 9, 2026

Multi-target T cell engagers redirecting immunity against intracellular cancer antigens in solid tumors.

Ternary Therapeutics

April 6, 2026

AI-driven platform designing molecular glue therapeutics for undruggable targets in immunology and neuroinflammation.

Stipple Bio

April 6, 2026

Epitope-resolution platform discovering tumor-specific cell surface targets for precision ADCs and next-generation oncology therapeutics.

TRIANA Biomedicines

April 4, 2026

Rational molecular glue degrader platform targeting undruggable oncology targets, with lead ALK fusion degrader in Phase 1/2 for NSCLC.

Commit Biologics

April 4, 2026

Bispecific complement engagers recruiting the innate immune system for B-cell depletion in autoimmune disease and cancer.

Neutrolis

April 4, 2026

Neutrolis is developing the first therapy designed to degrade neutrophil extracellular traps — attacking one of the root causes of autoimmunity without immunosuppression.

AvenCell Therapeutics

April 4, 2026

AvenCell just dosed the first patient with a CRISPR-engineered allogeneic CAR-T that simultaneously targets CD19 and CD20 — with a built-in switchable receptor that lets you retarget the same cells post-infusion.

Alltrna

April 4, 2026

Alltrna just put the first engineered tRNA therapeutic into a human trial, creating an entirely new drug class to address them.

Antiverse

March 9, 2026

Antiverse is using generative AI to crack the 220 undrugged GPCRs that conventional discovery can't touch.

NEOK Bio

March 9, 2026

NEOK is building on of the most ambitious bispecific ADC pipeline to hit the U.S. clinic.